World Congress on Precision Biotherapeutics - 2026
Explore the full spectrum of high-impact research tracks at WCPB. From next-generation ADC payload design to AI-driven drug discovery and clinical CMC scale-up.
Focused on targeted biopharmaceutical guided therapeutic delivery combining mAb systemic precision targeting with ultra-potent cytotoxic molecular payloads via cleavage-resistant chemical linkers, site-specific enzymatic conjugation, and drug-to-antibody ratio (DAR) optimization.
Harnessing post-transcriptional gene silencing via RNA interference, modified synthetic mRNA translation, antisense oligonucleotides (ASO), and microRNA modulators delivered via precision lipid nanoparticle (LNP) molecular transport systems.
Advanced chimeric antigen receptor T-cell (CAR-T / CAR-NK) engineering, in vivo CRISPR/Cas9 genomic editing, base editing, and viral/non-viral gene delivery platforms directed at monogenic and somatic diseases.
Biomarker-guided patient stratification, liquid biopsy circulating tumor DNA (ctDNA) assays, bispecific immune cell engagers, and personalized immunotherapeutic treatment regimens.
Targeted therapeutic discovery for ultra-rare monogenic disorders, gene replacement therapies, orphan drug designations, and expanding global clinical patient registries.
Harnessing generative AI, deep learning structural protein modeling (AlphaFold/ESMFold), in-silico binding affinity optimization, and machine learning models for CMC quality control.
Alpha/beta emitting isotopic bioconjugation (Actinium-225, Lutetium-177), PET/SPECT precision imaging dosimetry, and PROTAC targeted protein degradation platforms.
Overcoming analytical characterization bottlenecks, GMP scale-up, continuous bioprocessing, regulatory quality systems (QbD), and global cold-chain logistics.